fda compounding glp-1 enforcement news today 2025 november semaglutide The FDA has released new guidance for providers prescribing GLP-1 Shortage = Over Compounded Semaglutide & Tirzepatide 2025:

Deaths ( n = 60) in total occurred in the study, 25 (3%) in the tirzepatide arms and five (4%) in the insulin glargine arm (HR, 0.70

Researchers are responsible for compliance with all applicable regulations and institutional protocols

it included monk fruit sweetener in place of cane sugar, but definitely still had the decadence of a typical dessert

When youre taking semaglutide or another GLP-1, they can help you monitor your progress and recommend medication adjustments as needed for as long as theyre helping you achieve your goals

Liposomal formulations improve bioavailability marginally (perhaps 2535% vs 2030% for standard oral forms), but they cost 34 more